Biotech Company Auxilium Explodes After Takeover Offer
The offer values Auxilium at $28.10 per share and is comprised of an equal mix of cash and Endo stock.
Endo's offer represents a 31% premium to Auxilium's closing price on Tuesday, and a 40% premium to the closing price of Auxilium over the last 30 days. In after hours trade on Tuesday Auxilium shares were trading as high as $30.70.
Following the announcement, Endo shares were also higher, up more than 4%.
The offer also follows an announcement from Auxilium last week that the company would cut 30% of its staff as part of cost-saving measures aimed as saving $75 million per year.
Auxilium's portfolio of drugs includes: edex®, an injectable treatment for erectile dysfunction, Osbon® ErecAid®, a device for aiding erectile dysfunction, STENDRA®, an oral erectile dysfunction therapy, TESTOPEL®, a long-acting implantable testosterone replacement therapy, XIAFLEX®, for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture, among other drugs.
- Singapore Airlines was ordered to pay a couple compensation for 'mental agony' after they complained their business-class seats didn't automatically recline
- Welcome to the white-collar recession
- A software engineer shares the résumé he's used since college that got him a $500,000 job at Meta — plus offers at TikTok and LinkedIn
- Markets trade firm in early trade as GST revenues hit record in April
- Blockchain in Supply Chain Management
- Rupee turns flat at 83.43 against US dollar in early trade
- LS polls: EC increases polling time in Telangana in view of heat wave
- US Fed says further interest rate hike unlikely going ahead